Key Takeaways AbbVie shares dropped 5.2% as J&J secured FDA approval for Icotyde in plaque psoriasis.Skyrizi, AbbVie's top drug, posted $17.6B sales in 2025 and is key to post-Humira growth.Icotyde's oral delivery and expanding indications may intensify IL-23 competition over time.Shares of AbbVie (ABBV) fell 5.2% on Wednesday, wiping out more than $20 billion in market value. This selloff comes as investors grow wary of Johnson & Johnson’s (JNJ) newly approved immunology therapy, Icotyde, which could emerg ...

Core Viewpoint - Johnson & Johnson's new oral psoriasis medication, Icotyde, has received FDA approval, positioning it as a competitive alternative to existing injectable treatments in the market [1][2]. Group 1: Product Overview - Icotyde is the first oral treatment approved for moderate to severe plaque psoriasis, an autoimmune condition characterized by rough skin patches [1]. - The drug targets the IL-23 receptor, similar to popular injectable treatments like Tremfya and Skyrizi, providing patients with an oral option [2]. Group 2: Market Potential - Johnson & Johnson anticipates that Icotyde could become the first-line systemic treatment for psoriasis, bridging the gap between topical treatments and injections [2]. - The company estimates that peak annual sales for Icotyde could exceed $5 billion once it is approved for additional autoimmune conditions, including psoriatic arthritis, ulcerative colitis, and Crohn's disease [5]. Group 3: Patient Demographics and Appeal - Approximately 8 million people in the U.S. suffer from plaque psoriasis, with 75% of patients not progressing to injections due to needle aversion [3]. - The company believes that Icotyde's simple once-daily oral dosage will be appealing to patients who are hesitant to use injectable treatments [4]. Group 4: Competitive Landscape - The approval of Icotyde comes as the psoriasis treatment market becomes increasingly competitive, with drugmakers developing advanced therapies beyond standard topical treatments [2]. - Rival injectable treatments, such as Tremfya and Skyrizi, are priced around $100,000 annually, highlighting the potential market disruption Icotyde could cause [4].

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has been upgraded by Morgan Stanley from Equal Weight to Overweight, with a new price target of $262, indicating a positive outlook for the company's future performance [1][2]. Group 1: Analyst Insights - Terence Flynn from Morgan Stanley anticipates higher earnings estimates for Johnson & Johnson due to new product cycles, projecting earnings to exceed consensus estimates by nearly 20% [2][3]. - Flynn highlighted that Johnson & Johnson has one of the most robust new product cycles in the biopharma industry, raising estimates for products such as Tremfya, Icotyde, Tecvayli, and Darzalex [3]. Group 2: Stock Performance and Analyst Ratings - Over the past year, Johnson & Johnson shares have returned over 48.50%, with 57% of analysts rating it a Buy, 36% a Hold, and 7% a Sell [4]. - The median price target among analysts is $240, suggesting an upside of just under 6%, while Morgan Stanley's target of $262 indicates a potential upside of 15.25% [4]. Group 3: Company Overview - Johnson & Johnson is involved in the research, development, manufacturing, and sale of a variety of healthcare products globally, operating through two segments: Innovative Medicine and MedTech [5].